Atelerix

About:

Atelerix provides storage and transportation of human cells at room temperature to companies.

Website: https://www.atelerix.co.uk

Twitter/X: AtelerixLtd

Top Investors: Innovate UK, Future Planet Capital, Angels in MedCity, UK Innovation & Science Seed Fund, Newable Private Investing

Description:

Atelerix has a transformative technology for the storage and transport of viable cells at room temperature, overcoming the barriers and limitations presented by the current need for cryo-shipping. We do this using our patented process of encapsulating the cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer. This means: Predictability and reliability in drug discovery models and for cells used as therapies Customers can use cells and assays immediately on arrival No need for cryopreservation, nor need for cytotoxic or animal-derived supplements Cells retain their natural state and are not damaged nor altered

Total Funding Amount:

1.68M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Newcastle, Newcastle upon Tyne, United Kingdom

Founded Date:

2006-01-01

Contact Email:

mick.mclean(AT)atelerix.co.uk

Founders:

Che John Connon, Mick McLean, Stephen Swioklo

Number of Employees:

1-10

Last Funding Date:

2022-02-14

IPO Status:

Private

Industries:

© 2025 bioDAO.ai